Sarissa Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sarissa Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-360,000	Closed	-$5.85M	–	9
2017 Q1	$5.85M	Hold	360,000	–	–	2.31%	6
2016 Q4	$5.43M	Sell	360,000 -315,000	-47%	-$4.45M	1.5%	6
2016 Q3	$10.3M	Hold	675,000	–	–	2.37%	7
2016 Q2	$26.2M	Hold	675,000	–	–	7.44%	4
2016 Q1	$18.8M	Hold	675,000	–	–	4.13%	7
2015 Q4	$36.3M	Buy	675,000 +35,000	+5%	+$1.77M	7.06%	7
2015 Q3	$25.6M	Buy	640,000 +280,000	+78%	+$9.13M	6.33%	6
2015 Q2	$11.5M	Hold	360,000	–	–	2.65%	8
2015 Q1	$8.6M	Hold	360,000	–	–	1.81%	11
2014 Q4	$6.35M	Hold	360,000	–	–	2.25%	9
2014 Q3	$4.94M	Buy	360,000 +144,798	+67%	+$2.17M	1.91%	9
2014 Q2	$3.63M	Buy	215,202 +88,507	+70%	+$1.46M	1.23%	13
2014 Q1	$2.3M	Buy	+126,695	New	+$2.29M	0.79%	11

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Sarissa Capital Management's ITCI Position: Q2 2017 in Review

Sarissa Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2017, closing a stake of 360,000 shares — an estimated $5.85M sold.

Sarissa Capital Management first reported a position in ITCI in Q1 2014 and held it in 13 quarters. The position peaked at $36.3M in Q4 2015. 100 funds tracked by Wall St. Rank hold ITCI as of Q2 2017.

Sarissa Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2017 after selling out during the quarter.
Sarissa Capital Management sold 360,000 Intra-Cellular Therapies Inc. shares in Q2 2017, an estimated $5.85M.
Sarissa Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 13 quarters.
Sarissa Capital Management's Intra-Cellular Therapies Inc. position peaked at $36.3M in Q4 2015.
100 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2017.

Based on Sarissa Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.